Want to see ADPT full AI Analyst Report?
Adjusted EBITDA by Segment
Reveals profitability across different business units, highlighting which segments are driving earnings and operational efficiency.MRD has shifted from a recurring drag to the company’s primary profit engine—driven by volume, pricing and sequencing-margin improvements—and underpins management’s raised MRD guidance and 2026 profitability targets. Immune, however, is volatile: a single strong quarter looks nonrecurring and the segment reverted to losses, underscoring milestone timing, sample-processing variability and reimbursement risk; company-level improvement therefore depends on sustained MRD momentum or a clearer path to immune profitability to avoid misleading one-off spikes.
Date | MRD | Immune |
|---|---|---|
Mar 31, 2026 | $12.14M | -$10.36M |
Dec 31, 2025 | $10.42M | -$3.03M |
Sep 30, 2025 | $6.96M | $23.71M |
Jun 30, 2025 | $1.91M | -$6.07M |
Mar 31, 2025 | -$4.11M | -$5.45M |
Dec 31, 2024 | -$6.55M | -$6.83M |
Sep 30, 2024 | -$6.12M | -$5.21M |
Jun 30, 2024 | -$11.29M | -$7.03M |
Mar 31, 2024 | -$17.26M | -$6.93M |